vs
安进（AMGN）与KKR & Co.（KKR）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是KKR & Co.的1.7倍（$9.9B vs $5.7B），KKR & Co.净利率更高（20.0% vs 13.5%，领先6.5%），KKR & Co.同比增速更快（76.1% vs 8.6%），过去两年安进的营收复合增速更高（15.1% vs -22.9%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
KKR（全称Kohlberg Kravis Roberts & Co.）是源自美国的全球知名私募股权投资机构，截至2024年12月31日，已累计完成770笔私募股权投资，对应总企业价值约7900亿美元，资产管理规模达5530亿美元，其中付费资产管理规模为4460亿美元。
AMGN vs KKR — 直观对比
营收规模更大
AMGN
是对方的1.7倍
$5.7B
营收增速更快
KKR
高出67.6%
8.6%
净利率更高
KKR
高出6.5%
13.5%
两年增速更快
AMGN
近两年复合增速
-22.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $5.7B |
| 净利润 | $1.3B | $1.1B |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 45.3% |
| 净利率 | 13.5% | 20.0% |
| 营收同比 | 8.6% | 76.1% |
| 净利润同比 | 112.6% | 1.8% |
| 每股收益（稀释后） | $2.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNKKR
| Q4 25 | $9.9B | $5.7B | ||
| Q3 25 | $9.6B | $5.5B | ||
| Q2 25 | $9.2B | $5.1B | ||
| Q1 25 | $8.1B | $3.1B | ||
| Q4 24 | $9.1B | $3.3B | ||
| Q3 24 | $8.5B | $4.8B | ||
| Q2 24 | $8.4B | $4.2B | ||
| Q1 24 | $7.4B | $9.7B |
净利润AMGNKKR
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $3.2B | $900.4M | ||
| Q2 25 | $1.4B | $510.1M | ||
| Q1 25 | $1.7B | $-185.9M | ||
| Q4 24 | $627.0M | $1.1B | ||
| Q3 24 | $2.8B | $600.5M | ||
| Q2 24 | $746.0M | $667.9M | ||
| Q1 24 | $-113.0M | $682.2M |
毛利率AMGNKKR
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNKKR
| Q4 25 | 27.6% | 45.3% | ||
| Q3 25 | 26.4% | 39.8% | ||
| Q2 25 | 28.9% | 30.0% | ||
| Q1 25 | 14.5% | 24.8% | ||
| Q4 24 | 25.4% | 50.4% | ||
| Q3 24 | 24.1% | 34.3% | ||
| Q2 24 | 22.8% | 29.0% | ||
| Q1 24 | 13.3% | 14.1% |
净利率AMGNKKR
| Q4 25 | 13.5% | 20.0% | ||
| Q3 25 | 33.7% | 16.3% | ||
| Q2 25 | 15.6% | 10.0% | ||
| Q1 25 | 21.2% | -6.0% | ||
| Q4 24 | 6.9% | 34.5% | ||
| Q3 24 | 33.3% | 12.5% | ||
| Q2 24 | 8.9% | 16.0% | ||
| Q1 24 | -1.5% | 7.1% |
每股收益（稀释后）AMGNKKR
| Q4 25 | $2.45 | — | ||
| Q3 25 | $5.93 | — | ||
| Q2 25 | $2.65 | — | ||
| Q1 25 | $3.20 | — | ||
| Q4 24 | $1.17 | — | ||
| Q3 24 | $5.22 | — | ||
| Q2 24 | $1.38 | — | ||
| Q1 24 | $-0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | — |
| 总债务越低越好 | $54.6B | — |
| 股东权益账面价值 | $8.7B | $30.9B |
| 总资产 | $90.6B | $410.1B |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNKKR
| Q4 25 | $9.1B | — | ||
| Q3 25 | $9.4B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $12.0B | — | ||
| Q3 24 | $9.0B | — | ||
| Q2 24 | $9.3B | — | ||
| Q1 24 | $9.7B | — |
总债务AMGNKKR
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNKKR
| Q4 25 | $8.7B | $30.9B | ||
| Q3 25 | $9.6B | $29.7B | ||
| Q2 25 | $7.4B | $28.2B | ||
| Q1 25 | $6.2B | $27.5B | ||
| Q4 24 | $5.9B | $23.7B | ||
| Q3 24 | $7.5B | $24.1B | ||
| Q2 24 | $5.9B | $21.7B | ||
| Q1 24 | $5.0B | $21.4B |
总资产AMGNKKR
| Q4 25 | $90.6B | $410.1B | ||
| Q3 25 | $90.1B | $398.5B | ||
| Q2 25 | $87.9B | $380.9B | ||
| Q1 25 | $89.4B | $372.4B | ||
| Q4 24 | $91.8B | $360.1B | ||
| Q3 24 | $90.9B | $360.7B | ||
| Q2 24 | $90.9B | $348.5B | ||
| Q1 24 | $93.0B | $339.8B |
负债/权益比AMGNKKR
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $-4.9B |
| 自由现金流经营现金流 - 资本支出 | $961.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 6.5% | — |
| 现金转化率经营现金流/净利润 | 1.20× | -4.28× |
| 过去12个月自由现金流最近4个季度 | $8.1B | — |
8季度趋势，按日历期对齐
经营现金流AMGNKKR
| Q4 25 | $1.6B | $-4.9B | ||
| Q3 25 | $4.7B | $2.4B | ||
| Q2 25 | $2.3B | $438.8M | ||
| Q1 25 | $1.4B | $2.5B | ||
| Q4 24 | $4.8B | $-111.7M | ||
| Q3 24 | $3.6B | $1.9B | ||
| Q2 24 | $2.5B | $3.4B | ||
| Q1 24 | $689.0M | $1.5B |
自由现金流AMGNKKR
| Q4 25 | $961.0M | — | ||
| Q3 25 | $4.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $980.0M | — | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $459.0M | — |
自由现金流率AMGNKKR
| Q4 25 | 9.7% | — | ||
| Q3 25 | 44.4% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 48.4% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 26.5% | — | ||
| Q1 24 | 6.2% | — |
资本支出强度AMGNKKR
| Q4 25 | 6.5% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.0% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 3.1% | — |
现金转化率AMGNKKR
| Q4 25 | 1.20× | -4.28× | ||
| Q3 25 | 1.46× | 2.65× | ||
| Q2 25 | 1.59× | 0.86× | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 7.61× | -0.10× | ||
| Q3 24 | 1.26× | 3.12× | ||
| Q2 24 | 3.30× | 5.03× | ||
| Q1 24 | — | 2.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
KKR
| Insurance Segment | $3.5B | 61% |
| Asset Management1 | $703.7M | 12% |
| Transaction Fee | $512.0M | 9% |
| Transaction And Monitoring Fees | $268.7M | 5% |
| Fee Credit | $230.1M | 4% |
| Other | $201.5M | 4% |
| Fixed Annuity | $77.0M | 1% |
| Asset Management Segment | $56.9M | 1% |
| Monitoring Fee | $53.5M | 1% |
| Investment Advice | $40.6M | 1% |
| Fee Related Performance | $33.6M | 1% |
| Interest Sensitive Life | $21.7M | 0% |
| Incentive Fee | $11.0M | 0% |
